Table 1.
Participant demographics, ROS/MAP
| Dorsolateral prefrontal cortex bulk RNASeq | Caudate Nucleus bulk RNASeq | Posterior cingulate cortex bulk RNASeq | Dorsolateral prefrontal cortex TMT proteomics | |
|---|---|---|---|---|
| Sample size | 917 | 692 | 513 | 386 |
| AD pathological diagnosis, no. (%) | 554 (60) | 423 (61) | 299 (58) | 221 (57) |
| AD clinical diagnosis, no. (%) | 393 (43) | 276 (40) | 192 (37) | 122 (32) |
| MCI clinical diagnosis, no. (%) | 229 (25) | 188 (27) | 134 (26) | 98 (25) |
| No cognitive impairment, no. (%) | 295 (32) | 228 (33) | 187 (36) | 166 (43) |
| APOE-ε4 carrier, no. (%) | 234 (26) | 187 (27) | 130 (26) | 79 (20) |
| Non-hispanic white, no. (%) | 903 (98) | 686 (99) | 504 (98) | 370 (96) |
| Female, no. (%) | 597 (65) | 450 (65) | 318 (62) | 271 (70) |
| Age at death (years) | 89.42 ± 6.69 | 89.33 ± 6.46 | 89.34 ± 6.55 | 89.31 ± 6.51 |
| Education (years) | 16.38 ± 3.54 | 16.3 ± 3.54 | 16.38 ± 3.51 | 15.79 ± 3.55 |
| Average follow-up time (years) | 7.54 ± 4.97 | 7.66 ± 4.83 | 7.47 ± 4.86 | 8.75 ± 4.46 |
| Global cognition score (last visit) | −0.8 ± 1.06 | −0.78 ± 1.07 | −0.7 ± 1.05 | −0.51 ± 1.03 |
| Post-mortem interval (hours) | 7.56 ± 4.32 | 7.62 ± 4.39 | 7.02 ± 4.04 | 8.06 ± 5.46 |
| CERAD, “moderate” or “frequent”, no. (%) | 599 (65) | 455 (66) | 320 (62) | 241 (62) |
| Braak III–VI, no. (%) | 760 (83) | 579 (84) | 417 (81) | 313 (81) |
Values are mean ± standard deviation or number of samples (percent of the group)
Consortium to establish a registry for Alzheimer’s disease (CERAD) protocol for neuritic amyloid plaque density scores: (“none”, “sparse”, “moderate”, or “frequent”). Braak staging for neurofibrillary tangle distribution and severity (from 0; least severe, to VI; most severe)
AD Alzheimer’s disease, MCI mild cognitive impairment, APOE-ε4 apolipoprotein E epsilon 4